Axsome Common Stock vs Other Current Liab Analysis
AXSM Stock | USD 71.71 0.19 0.27% |
Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Common Stock and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
Common Stock vs Other Current Liab
Common Stock vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Common Stock account and Other Current Liab. At this time, the significance of the direction appears to have strong relationship.
The correlation between Axsome Therapeutics' Common Stock and Other Current Liab is 0.61. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Common Stock and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Axsome Therapeutics are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Common Stock i.e., Axsome Therapeutics' Common Stock and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.61 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Common Stock
Other Current Liab
Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 27th of April 2024, Tax Provision is likely to grow to about 1 M, while Sales General And Administrative To Revenue is likely to drop 0.78.
Axsome Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Axsome Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Axsome Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 220.5M | 186.1M | (338.4M) | 331.5M | 588.2M | 617.6M | |
Short Long Term Debt Total | 19.9M | 50.1M | 49.7M | 94.7M | 186.4M | 195.7M | |
Other Current Liab | 683.2K | 8.7M | 9.3M | 57.5M | 96.9M | 101.8M | |
Total Current Liabilities | 24.5M | 23.4M | 23.1M | 96.6M | 138.9M | 145.8M | |
Total Stockholder Equity | (175.9M) | (278.8M) | (409.2M) | 109.6M | 191.0M | 200.5M | |
Net Debt | (200.0M) | (133.8M) | (36.8M) | (106.2M) | (199.8M) | (189.8M) | |
Retained Earnings | (175.9M) | (278.8M) | (409.2M) | (596.3M) | (835.6M) | (793.8M) | |
Accounts Payable | 10.9M | 13.5M | 13.1M | 38.6M | 40.7M | 42.7M | |
Cash | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Cash And Short Term Investments | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Common Stock Total Equity | 3.0K | 3.7K | 3.7K | 3.8K | 4.3K | 2.7K | |
Common Stock Shares Outstanding | 34.0M | 37.2M | 37.6M | 40.7M | 45.4M | 30.1M | |
Liabilities And Stockholders Equity | (134.1M) | (206.5M) | (338.4M) | 331.5M | 588.2M | 617.6M | |
Other Current Assets | 413.1K | 148.4K | 45.3K | 2.8M | 8.1M | 8.5M | |
Other Stockholder Equity | (3.7K) | (3.7K) | (3.8K) | 705.9M | 1.0B | 1.1B | |
Total Liab | 41.8M | 72.3M | 70.8M | 221.9M | 397.3M | 417.1M | |
Total Current Assets | 220.4M | 184.0M | 86.5M | 245.6M | 504.3M | 529.5M | |
Short Term Debt | 2.6M | 1.2M | 620.7K | 424.7K | 1.3M | 1.3M | |
Common Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 3.2K | |
Net Tangible Assets | 178.7M | 113.8M | 15.6M | 39.6M | 45.5M | 52.6M | |
Non Current Assets Total | 170.5K | 2.1M | 1.3M | 85.8M | 84.0M | 88.2M | |
Non Currrent Assets Other | 139.9K | 317.4K | 322.9K | 14.7M | 11.0M | 11.6M | |
Other Assets | 139.9K | 2.1M | (426.1M) | 14.7M | 13.2M | 13.9M | |
Long Term Debt | 17.3M | 48.3M | 49.1M | 94.3M | 178.1M | 187.0M | |
Non Current Liabilities Total | 17.3M | 48.9M | 49.1M | 125.4M | 258.4M | 271.3M | |
Property Plant And Equipment Net | 30.6K | 1.8M | 944.0K | 1.1M | 7.6M | 8.0M | |
Property Plant And Equipment Gross | 30.6K | 1.8M | 944.0K | 1.1M | 7.6M | 8.0M | |
Property Plant Equipment | 30.6K | 52.6K | 283.8K | 1.1M | 1.3M | 1.4M | |
Retained Earnings Total Equity | (107.6M) | (175.9M) | (278.8M) | (409.2M) | (368.3M) | (349.9M) | |
Long Term Debt Total | 3.6M | 17.3M | 48.3M | 49.1M | 56.5M | 59.3M | |
Capital Surpluse | 108.5M | 354.6M | 392.6M | 424.8M | 488.5M | 264.6M | |
Net Invested Capital | 198.7M | 162.1M | 64.7M | 203.8M | 369.0M | 387.5M | |
Net Working Capital | 195.9M | 160.6M | 63.5M | 149.1M | 365.4M | 383.7M | |
Capital Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 4.3K |
Pair Trading with Axsome Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Axsome Stock
0.86 | RZLT | Rezolute Financial Report 9th of May 2024 | PairCorr |
0.79 | HCWB | HCW Biologics | PairCorr |
0.77 | RVMD | Revolution Medicines Financial Report 13th of May 2024 | PairCorr |
0.73 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.62 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Axsome Stock analysis
When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.27) | Revenue Per Share 5.957 | Quarterly Revenue Growth 1.935 | Return On Assets (0.25) | Return On Equity (1.59) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.